Compare FIEE & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FIEE | ELOX |
|---|---|---|
| Founded | 1977 | N/A |
| Country | Hong Kong | United States |
| Employees | 3 | 7 |
| Industry | Telecommunications Equipment | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7M | 41.0M |
| IPO Year | N/A | N/A |
| Metric | FIEE | ELOX |
|---|---|---|
| Price | $3.19 | $17.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 694.0K | 55.5K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $10.00 |
| 52 Week High | $10.59 | $19.36 |
| Indicator | FIEE | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 46.08 | 67.66 |
| Support Level | $2.01 | $10.74 |
| Resistance Level | $4.46 | $19.36 |
| Average True Range (ATR) | 1.10 | 2.00 |
| MACD | 0.05 | 0.72 |
| Stochastic Oscillator | 10.87 | 80.34 |
FiEE Inc is a digital service provider focused on integrating artificial intelligence (AI) and data analytics into content creation, digital authentication, and brand management. Its business model leverages a cloud-based SaaS platform designed to support clients in developing, managing, and optimizing their digital presence across platforms, including customized graphics and posts, short videos, and editorial calendars aligned with brand goals. Additionally, it offers comprehensive software development and maintenance services, delivering custom software solutions from system design and development to deployment and post-launch maintenance. It services consist of three core areas: digital content and MCN services, software development services, and digital authentication services.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.